Nicotine promotes the progression and metastasis of non-small cell lung cancer by modulating the OTUB1-c-Myc-EZH2 axis
“Smoking has been identified as a major risk factor for the development and progression of non-small cell lung cancer (NSCLC). As a key component of tobacco smoke, nicotine is believed to play a significant role in promoting NSCLC growth and progression. EZH2 is an epigenetic regulator highly expressed in the tumor tissues of smokers. However, whether and how nicotine regulates the expression of EZH2 and the underlying mechanisms remain unclear.”
Lung Cancer Screening Rates Increased After 2021 Update to USPSTF Guidelines
“Increased lung cancer screening uptake was seen after the 2021 update to the U.S. Preventive Services Task Force (USPSTF) guidelines, which expanded eligibility criteria to include adults aged 50 to 80 years with a smoking history of 20 or more pack-years, according to a research letter published online March 20 in JAMA Oncology.”
Early Lung Cancer Identification
“NEW YORK–(BUSINESS WIRE)–University Hospitals Cleveland Medical Center (UH) has announced a groundbreaking collaboration with global healthcare Artificial Intelligence (AI) innovator Qure.ai to deploy chest X-ray AI, supporting earlier identification of lung cancers. The FDA cleared chest X-ray AI solution qXR-LN will act as a second read, to be compared to the radiologists’ read of patient chest X-rays for any suspicious lung nodules. This will also provide evidence for future AI research.”
Addressing low lung cancer screening rates through awareness and access
“Lung cancer screening has the potential to catch lung cancer early and save lives-but only if people get screened. Although lung cancer screening is recommended in the U.S. for certain individuals with a history of smoking, only 18% of eligible individuals in the U.S. get screened. One suggested explanation has been that those eligible are resistant to receiving preventive healthcare, but a new study published in JAMA and led by researchers at Mass General Brigham indicates otherwise.”
Particulate matter air pollution as a cause of lung cancer: epidemiological and experimental evidence
“Air pollution has a significant global impact on human health. Epidemiological evidence strongly suggests that airborne particulate matter (PM), the dust components of polluted air, is associated with increased incidence and mortality of lung cancer. PM2.5 (PM less than 2.5 µm) from various sources carries different toxic substances, such as sulfates, organic compounds, polycyclic aromatic hydrocarbons, and heavy metals, which are considered major carcinogens that increase lung cancer risk.”
‘Grandma, were you afraid to die?’ Reader has one big reason to beat lung cancer
“Happy birthday Sloane! Eight years old, tomorrow. Sorry about being early, but my column doesn’t run on Tuesdays, and in my profession — newspapering, ask your grandmother about it — a day early is far better than a day late.”
Imdelltra May Improve Survival in Small Cell Lung Cancer
“Imdelltra (tarlatamab-dlle) has shown statistically significant and clinically meaningful improvement in overall survival compared to local standard-of-care chemotherapy among patients with small cell lung cancer (SCLC) whose disease has progressed on or after a single line of platinum-based chemotherapy, it has been announced.”
Lung Cancer: Mortality Trends in Veterans and New Treatments
“The annual incidence rate of lung cancer among veterans is substantial and increasing, tripling from 2000 to 2017; historically, it was largely due to higher rates of smoking. In recent years, the VHA has aimed to improve survival rates of patients with lung cancer across all disease stages and racial/ethnic groups.2 These efforts include providing increased screening, molecular testing, and access to targeted therapies; adopting advanced surgical and biopsy techniques; and implementing nurse navigators to guide care.”
Some lung cancer patients maintain long-term control after stopping immunotherapy
“Bottom line: A subset of patients with non-small cell lung cancer (NSCLC) who discontinued immune checkpoint inhibitor (ICI) therapy due to immune-related adverse events (irAEs) continued to experience long-term disease control.”
First Patient Dosed in a Phase 1/2 Trial for Small Cell Lung Cancer
“Key Takeaways: Iadademstat, a selective LSD1 inhibitor, is being tested with immune checkpoint inhibitors for extensive-stage SCLC in a phase 1/2 trial. The trial, led by the National Cancer Institute, evaluates safety, tolerability, and efficacy in patients post-chemoimmunotherapy.”
The dual role of microRNAs in lung cancer progression and suppression
“Lung cancer (LC) is a major global health issue, with high mortality rates and limited therapeutic options. It is primarily categorized into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Despite significant advancements in diagnostic techniques, LC remains highly lethal, largely due to late-stage diagnosis and aggressive metastasis. Recent research has emphasized the pivotal role of microRNAs (miRNAs) in the pathogenesis of LC.”
High-Dose Radiotherapy Boosts Survival Without Toxicity Increase in LS-SCLC
“Hyper-fractionated twice-daily radiotherapy conferred an overall survival (OS) improvement vs standard-dose radiation without increasing toxicity among patients with limited-stage small cell lung cancer (LS-SCLC), according to findings from a phase 3 study (NCT03214003) published in Lancet Respiratory Medicine.”
